£75.84

Springer Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)

Price data last checked 56 day(s) ago - refreshing...

View at Amazon

Price History & Forecast

Last 35 days • 35 data points (No recent data available)

Historical
Generating forecast...
£75.84 £72.30 £73.07 £73.84 £74.62 £75.39 £76.16 25 January 2026 02 February 2026 11 February 2026 19 February 2026 28 February 2026

Price Distribution

Price distribution over 35 days • 2 price levels

Days at Price
Current Price
18 days 17 days · current 0 5 9 14 18 £73 £76 Days at Price

Price Analysis

Most common price: £73 (18 days, 51.4%)

Price range: £73 - £76

Price levels: 2 different prices over 35 days

Description

Product Description This book represents an up-dated summary of the state of the art of the characterization of cancer stem cell/ cancer initiating cell (CSC/CIC) properties. An overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies is provided. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients. From the Back Cover This book represents an updated summary of the state of the art of the characterization of cancer stem cell/cancer initiating cell (CSC/CIC) properties. Experts provide an overview of the definition and biological properties of CSCs/CICs as well as the role of these cells in determining the resistance to standard and immune-based therapies. It also discusses limitations in the achievement of a definitive biological characterization of CSCs/CICs due to their high extent of plasticity and heterogeneity that is also mutually driven by the interaction of these cells with the tumor microenvironment. The limitations in targeting CSCs/CICs with immunotherapy are also explained together with explorative combination approaches that could increase the susceptibility of these cells to the recognition by immune cells. This book is conceived for a broad audience, including students, teachers, scientific experts. The critical revision of available results in terms of immunological profile of CSCs/CICs and the efficacy in targeting these cells by immunological approaches, results in a comprehensive and up to date recapitulation of the field and provides interesting suggestions on how to focus future investigations in order to assess the role of CSCs/CICs as prognostic and predictive biomarkers of responsiveness to therapies for cancer patients. About the Author Dr. Cristina Maccalli is a Staff Scientist at the Division of Translational Medicine, Sidra Medicine, Doha, Qatar. Dr. Maccalli obtained a Master’s Degree in Biological Sciences and a Ph.D. in Applied Genetics at the University of Milan, Italy. Her research interest lies in the area of immunology, tumor immunology and immunotherapy, with main focus on the functional characterization of immune responses, cancer stem cells and on the identification of biomarkers predictive of patients’ clinical outcome and responsiveness to therapies. She carried out her post-doctoral research programs at the National Cancer Institute in Milan, Italy and, then, at the Surgery Branch, National Cancer Institute, NIH, Bethesda, MD, USA. Most recently, Dr. Maccalli joined the Translational Medicine Department at Sidra Medical and Research Center, Doha, Qatar, where she is involved in development of innovative studies in the context of biomarker discovery and immunotherapy. Her principle project areas are 1. the generation of chimeric receptor engineered T cells to target hematological malignancies; 2. The molecular and functional characterization of cancer stem cells isolated from colorectal and breast cancer patients and 3. the identifica

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
17 June 2019
Listed Since
27 February 2019

Barcode

No barcode data available

Similar Products You Might Like

Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)
97% match

Cancer Stem Cell Resistance to Targeted Therapy: 19 (Resistance to Targeted Anti-Cancer Therapeutics, 19)

Springer

£75.30 09 Mar 2026
Cancer Stem Cells: New Horizons in Cancer Therapies
95% match

Cancer Stem Cells: New Horizons in Cancer Therapies

Springer

£76.73 23 Feb 2026
Stem Cells and Cancer (Cancer Drug Discovery and Development)
95% match

Stem Cells and Cancer (Cancer Drug Discovery and Development)

Humana

£149.20 27 Jan 2026
Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy)
95% match

Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives (Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy)

Academic Press

£111.19 12 Apr 2026
Stem Cells and Cancer (Cancer Drug Discovery and Development)
95% match

Stem Cells and Cancer (Cancer Drug Discovery and Development)

Humana

£148.78 19 Apr 2026
CRC Press Rediscovering Cancer: From Mechanism to Therapy
94% match

CRC Press Rediscovering Cancer: From Mechanism to Therapy

CRC Press

£112.08 14 Apr 2026
Rediscovering Cancer: From Mechanism to Therapy
94% match

Rediscovering Cancer: From Mechanism to Therapy

CRC Press

£76.70 26 Feb 2026
Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)
94% match

Targeted Therapies: Mechanisms of Resistance (Molecular and Translational Medicine)

Humana

£102.99 04 Apr 2026
Springer - Resistance to Immunotherapeutic Antibodies in Cancer
94% match

Springer - Resistance to Immunotherapeutic Antibodies in Cancer

Springer

£107.61 17 Apr 2026
Stem Cell Therapeutics for Cancer
94% match

Stem Cell Therapeutics for Cancer

Wiley

£98.00 08 Mar 2026
Springer - Novel Immunotherapeutic Approaches to Cancer Treatment
94% match

Springer - Novel Immunotherapeutic Approaches to Cancer Treatment

Springer

£108.91 20 Apr 2026
Springer - Novel Immunotherapeutic Approaches to Cancer Treatment
94% match

Springer - Novel Immunotherapeutic Approaches to Cancer Treatment

Springer

£113.48 18 Apr 2026
Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance
94% match

Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance

Academic Press

£98.89 09 Mar 2026
Targeted Therapies in Oncology
94% match

Targeted Therapies in Oncology

CRC Press

£105.94 25 Feb 2026
Targeted Cancer Immune Therapy
94% match

Targeted Cancer Immune Therapy

Springer

£145.51 11 Jan 2026
Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development)
94% match

Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development)

Humana

£147.91 10 Mar 2026
Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development)
94% match

Macromolecular Anticancer Therapeutics (Cancer Drug Discovery and Development)

Humana

£117.40 15 Jan 2026
Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy: 1036 (Advances in Experimental Medicine and Biology, 1036)
94% match

Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy: 1036 (Advances in Experimental Medicine and Biology, 1036)

Springer

£96.55 09 Mar 2026
Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal
94% match

Tumor-Induced Immune Suppression: Mechanisms and Therapeutic Reversal

Springer

£129.22 04 Mar 2026
Targeted Therapies in Oncology
94% match

Targeted Therapies in Oncology

CRC Press

£56.99 20 Feb 2026
Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)
94% match

Resistance to Targeted Therapies in Lymphomas: 21 (Resistance to Targeted Anti-Cancer Therapeutics, 21)

Springer

£65.04 28 Feb 2026
Cancer Stem Cells: Basic Concept and Therapeutic Implications
94% match

Cancer Stem Cells: Basic Concept and Therapeutic Implications

£101.94 12 Jan 2026
Cancer Stem Cells: Basic Concept and Therapeutic Implications
94% match

Cancer Stem Cells: Basic Concept and Therapeutic Implications

£150.17 10 Jan 2026
From Molecular to Modular Tumor Therapy:: Tumors are Reconstructible Communicatively Evolving Systems: 3 (The Tumor Microenvironment, 3)
94% match

From Molecular to Modular Tumor Therapy:: Tumors are Reconstructible Communicatively Evolving Systems: 3 (The Tumor Microenvironment, 3)

Springer

£149.65 30 Mar 2026